The effects of TPST-1120 as monotherapy or in combination with chemotherapy or anti-PD1 were evaluated in multiple syngeneic mouse models including B16 melanoma, MMTV mammary carcinoma, MC38 colon, Lewis lung carcinoma, ID8 ovarian, Panc07 pancreatic cancer, and xenograft CLL, melanoma, pancreatic and AML models. Here, PDCD1 is linked to breast carcinoma.